Adult Dosing
Mild to moderate active Crohn's disease involving the ileum and/or the ascending colon
Entocort EC, budesonide
- 9 mg PO qam up to 8 wks; may repeat an 8 wk course
Maintenance of remission Crohn's Disease
Entocort EC, budesonide
- 6 mg PO qd x up to 3 month. Taper other systemic steroids when transferring to budesonide
- If symptom control is maintained at 3 months, an attempt to taper to complete cessation is recommended
Mild to moderate ulcerative colitis
Uceris
Note:
- Do not cut, crush, or chew the tablet
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Chickenpox and measles may have a more serious course in patients on oral glucocorticosteroids. In patients who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered
- Monitor for hypercorticism in moderate to severe liver disease; consider reducing dose
- Supplement with more steroids in physiologic stress
- Care is needed in patients who are transferred from glucocorticosteroid with high systemic availability
- When budesonide is used chronically in excessive doses, systemic glucocorticosteroid effects such as hypercorticism and adrenal suppression may appear
Cautions: Use cautiously in
- Hepatic impairment
- Systemic fungal, viral, or mycobacterial infections
- Hypertension
- Diabetes mellitus
- Osteoporosis
- Peptic ulcer disease
- Glaucoma
- Cataracts
- CHF
- Seizure disorder
- Tuberculosis
- Elderly patients
Supplemental Patient Information
- Patients should be advised to avoid the consumption of grapefruit juice for the duration of their therapy
Pregnancy Category:C
Breastfeeding: Manufacturer recommends to discontinue nursing or treatment, taking into account the importance of the drug to the mother.
US Trade Name(s)
US Availability
budesonide (generic)
Entocort EC
Uceris
Canadian Trade Name(s)
Canadian Availability
Entocort
UK Trade Name(s)
- Entocort CR
- Budenofalk 3mg gastro-resistant capsules
UK Availability
Entocort CR
Budenofalk 3mg gastro-resistant capsules
Australian Trade Name(s)
Australian Availability
Entocort
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Entocort EC 3 MG CP24 [Bottle] (ASTRAZENECA)
30 mg = $549.97
90 mg = $1559.96 - Buprenorphine HCl 8 MG SUBL [Bottle] (ROXANE)
30 mg = $99.99
60 mg = $195 - Buprenorphine HCl 2 MG SUBL [Bottle] (ROXANE)
30 mg = $75.99
90 mg = $199.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Entocort EC 3 MG 24 HR Extended Release Capsule
Ingredient(s): Budesonide
Imprint: ENTOCORT;EC;3;mg
Color(s): Gray
Shape: Capsule
Size (mm): 7.00
Score: 1
Inactive Ingredient(s): acetyltributyl citrate / methacrylic acid / triethyl citrate / polysorbate 80 / talc / gelatin / ferrosoferric oxide / titanium dioxide / colloidal silicon dioxide / ferric oxide yellow / ferric oxide red
Drug Label Author:
Prometheus Laboratories Inc
DEA Schedule:
Non-Scheduled
